475 related articles for article (PubMed ID: 21258646)
1. Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy.
Wagner JM; Hackanson B; Lübbert M; Jung M
Clin Epigenetics; 2010 Dec; 1(3-4):117-136. PubMed ID: 21258646
[TBL] [Abstract][Full Text] [Related]
2. Targeting histone methyltransferases and demethylases in clinical trials for cancer therapy.
Morera L; Lübbert M; Jung M
Clin Epigenetics; 2016; 8():57. PubMed ID: 27222667
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic therapy of cancer with histone deacetylase inhibitors.
Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC
J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724
[TBL] [Abstract][Full Text] [Related]
4. [DNA methyltransferase inhibitors * histone deacetylase inhibitors].
Kikuchi J; Furukawa Y
Nihon Rinsho; 2014 Jun; 72(6):1136-42. PubMed ID: 25016817
[TBL] [Abstract][Full Text] [Related]
5. Chemical Tools with Fluorescence Switches for Verifying Epigenetic Modifications.
Hori Y; Kikuchi K
Acc Chem Res; 2019 Oct; 52(10):2849-2857. PubMed ID: 31577127
[TBL] [Abstract][Full Text] [Related]
6. HDAC modulation and cell death in the clinic.
Dell'Aversana C; Lepore I; Altucci L
Exp Cell Res; 2012 Jul; 318(11):1229-44. PubMed ID: 22336671
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic therapies in patients with solid tumors: Focus on monotherapy with deoxyribonucleic acid methyltransferase inhibitors and histone deacetylase inhibitors.
Katarzyna R; Lucyna B
J Cancer Res Ther; 2019; 15(5):961-970. PubMed ID: 31603095
[TBL] [Abstract][Full Text] [Related]
8. Epigenetics and cancer treatment.
Kristensen LS; Nielsen HM; Hansen LL
Eur J Pharmacol; 2009 Dec; 625(1-3):131-42. PubMed ID: 19836388
[TBL] [Abstract][Full Text] [Related]
9. Epigenomic networking in drug development: from pathogenic mechanisms to pharmacogenomics.
Cacabelos R
Drug Dev Res; 2014 Sep; 75(6):348-65. PubMed ID: 25195579
[TBL] [Abstract][Full Text] [Related]
10. Treatment of cardiovascular pathology with epigenetically active agents: Focus on natural and synthetic inhibitors of DNA methylation and histone deacetylation.
Chistiakov DA; Orekhov AN; Bobryshev YV
Int J Cardiol; 2017 Jan; 227():66-82. PubMed ID: 27852009
[TBL] [Abstract][Full Text] [Related]
11. An Update of Epigenetic Drugs for the Treatment of Cancers and Brain Diseases: A Comprehensive Review.
Sahafnejad Z; Ramazi S; Allahverdi A
Genes (Basel); 2023 Apr; 14(4):. PubMed ID: 37107631
[TBL] [Abstract][Full Text] [Related]
12. Recent Advances in Computer-Assisted Structure-Based Identification and Design of Histone Deacetylases Inhibitors.
Krishna S; Kumar V; Siddiqi MI
Curr Top Med Chem; 2016; 16(9):934-47. PubMed ID: 26303428
[TBL] [Abstract][Full Text] [Related]
13. Histone Deacetylase Inhibitors as Cognitive Enhancers and Modifiers of Mood and Behavior.
Pal D; Sahu P; Mishra AK; Hagelgans A; Sukocheva O
Curr Drug Targets; 2023; 24(9):728-750. PubMed ID: 36475351
[TBL] [Abstract][Full Text] [Related]
14. Histone deacetylase inhibitors: recent insights from basic to clinical knowledge & patenting of anti-cancer actions.
Carafa V; Nebbioso A; Altucci L
Recent Pat Anticancer Drug Discov; 2011 Jan; 6(1):131-45. PubMed ID: 21110829
[TBL] [Abstract][Full Text] [Related]
15. [Epigenetic mechanisms and alcohol use disorders: a potential therapeutic target].
Legastelois R; Jeanblanc J; Vilpoux C; Bourguet E; Naassila M
Biol Aujourdhui; 2017; 211(1):83-91. PubMed ID: 28682229
[TBL] [Abstract][Full Text] [Related]
16. Histone modification and histone modification-targeted anti-cancer drugs in breast cancer: Fundamentals and beyond.
Feng J; Meng X
Front Pharmacol; 2022; 13():946811. PubMed ID: 36188615
[TBL] [Abstract][Full Text] [Related]
17. Targeting epigenetic DNA and histone modifications to treat kidney disease.
Fontecha-Barriuso M; Martin-Sanchez D; Ruiz-Andres O; Poveda J; Sanchez-Niño MD; Valiño-Rivas L; Ruiz-Ortega M; Ortiz A; Sanz AB
Nephrol Dial Transplant; 2018 Nov; 33(11):1875-1886. PubMed ID: 29534238
[TBL] [Abstract][Full Text] [Related]
18. Advances in Epigenetic Cancer Therapeutics.
Hillyar C; Rallis KS; Varghese J
Cureus; 2020 Nov; 12(11):e11725. PubMed ID: 33391954
[TBL] [Abstract][Full Text] [Related]
19. Histone modification enhances the effectiveness of IL-13 receptor targeted immunotoxin in murine models of human pancreatic cancer.
Fujisawa T; Joshi BH; Puri RK
J Transl Med; 2011 Apr; 9():37. PubMed ID: 21477288
[TBL] [Abstract][Full Text] [Related]
20. Histone modifications in epigenetic regulation of cancer: Perspectives and achieved progress.
Neganova ME; Klochkov SG; Aleksandrova YR; Aliev G
Semin Cancer Biol; 2022 Aug; 83():452-471. PubMed ID: 32814115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
